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Small cell carcinoma (SmCC) is a distinct clinicopathological entity first described in the lung. It represents
approximately 15% of all bronchogenic carcinoma. Extrapulmonary small cell carcinoma (EPSmCC) morphologically
indistinguishable from small cell lung cancer (SCLC) was first reported in 1930. Since its first description, EPSmCC
has been reported in virtually all anatomical sites, including: gynecologic organs (ovary and cervix); genitourinary
organs (urinary bladder and prostate); the gastrointestinal tract (esophagus); skin (Merkel cell carcinoma) and head
and neck region. Regardless of the anatomic sites, all SmCCs have similar, if not identical, histo-pathology features
and immunohistochemical profile. SmCC is one of the most aggressive malignancies. The molecular mechanisms
underlying its development and progression remain poorly understood. Herein, we reviewed the literature in SmCC
in respect to its site of occurrence, clinical features, immunohistochemical characteristics. SmCCs have heterogeneous
molecular mutations. Dinstinct genetic alterations associated with SmCC from different body sites were reviewed. Some
genetic alterations such as RB1, TP53 are commonly seen in different origins of SmCC. Other genes with site specificity
were also summarized, such as bladder SmCC with TERT promoter mutations; prostate SmCC with ERG translocations;
ovarian SmCC with SMARCA4 mutations; Merkel cell carcinoma (skin) and cervical SmCC with Merkel cell polyomavirus
(MCV or MCPyV) and human papillomavirus (HPV). Further studies are needed to employ a genetically oriented
approach for the diagnosis and therapy of SmCC.Introduction
Small-cell carcinoma ("oat-cell carcinoma") is a type of
highly malignant cancer that commonly arises in the
lung. Uncommonly, small-cell carcinoma arising from
outside of the lungs and pleura is referred to as extrapul-
monary small-cell carcinoma (EPSmCC). The diagnosis
of SmCC is primarily based on path-histologic criteria:
sheets, ribbons, clusters, rosettes or peripheral palisading
of small to medium sized (2-4x neutrophils) round/oval
cells with minimal cytoplasm, salt and pepper chromatin
without prominent clumps, hyperchromatic, indistinct
nucleoli, nuclear molding, smudging, frequent mitotic
figures (Figure 1A). In addition, SmCC cells show neuro-
endocrine differentiation and are positive for neuroendo-
crine tissue markers: chromogranin and synaptophysin
(Figure 1B and C). The clinical behavior of SmCC from
different anatomic sites are quite similar. SmCC cells
usually metastasize very early, respond dramatically to* Correspondence: zhongm@wcmc.com; delong_liu@nymc.edu
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unless otherwise stated.chemotherapy (CT) and radiation therapy (RT) [1].
Patients usually have a very poor prognosis and short
survival time despite treatment. Treatment of SmCC of
lung and EPSmCC is similar. However, recent evidence
at molecular and genetic levels suggests that SmCC from
different anatomic sites may have distinct genetic bio-
markers and is a heterogenous group of diseases. This
conceptual change is critical for better understanding of
these aggressive malignancies and may lead to a genetic-
ally oriented approach for the diagnosis and targeted
therapy of SmCC.
I. Small-cell lung cancer
Small-cell lung cancer (SCLC), representing 15% of all
bronchogenic carcinoma cases, is a distinct subtype as-
sociated with a typical clinical picture of early metastasis.
Chemotherapy alone or combined with radiation, but
not surgery, is the usual treatment of choice for small
cell lung cancer. On this regimen, a large percentage of
patients experiences remission. The 5-year survival for
small cell lung cancer (6%) is however much lower than
that for non-small cell lung cancer (NSCLC) (18%). OneThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Morphology of small cell carcinoma. H&E staining x400 (A); Immunohistochemistry of chromogranin (B) and synaptophysin (C).
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used for NSCLC treatment, and mutation analysis is
routinely done now for EGFR, KRAS, or ALK. More and
more novel agents for targeted therapy of NSCLC are
being developed [2-4].
As for SmCC, several tumor suppressor genes are
inactivated, including TP53 (80–90% of cases, [5]) RB1
(60–90% of cases [6,7]) and PTEN (13% of cases [8]). In
mice, SCLC is initiated by deletion of two tumor sup-
pressor genes (RB1 and TP53). Deletion of these two
genes produces a model that recapitulates the clinical
features of human SCLC. Infrequent activating muta-
tions have also been found in PIK3CA, EGFR and KRAS
(all 10% or lower). In addition, MYC is amplified in 20%
of cases [9]. Mean levels of total PARP1 (a DNA repair
protein and E2F1 co-activator) were higher in SCLC cell
lines than in NSCLC cell lines, and SCLC growth was
inhibited by PARP1 and EZH2 knockdown [10].II. Small cell carcinoma of genitourinary tract
The genitourinary tract is the most common extrapul-
monary site for EPSmCC, with approximately 900 new
cases diagnosed every year in the United States [11]. The
most common sites for SmCC of the genitourinary tract
are the urinary bladder and prostate; however, it is still
very rare, accounting for only 0.7% and 0.5% of all bladder
and prostate cancer, respectively. SmCC of the genitouri-
nary tract is an aggressive cancer, with a poor prognosis
overall. Although there is no standard of care, patients are
treated using a multimodality approach analogous to
those used in the treatment of small-cell lung cancer [12].
1. Renal SmCC is an extremely rare malignancy and
accounts for less than 1% of all renal tumors.
Although renal SmCC shares similar morphological
and immunohistochemical features with SmCC of
other organs, renal SmCC often (60-70%) coexists
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a potential association between SmCC and
urothelial carcinoma in the kidney [13,14].
Renal SmCC affects patients of various ages
and appears to be more common in men
(male–female ratio = 2:1) [14]. Its clinical
presentations are similar to those of renal cell
carcinoma or urothelial carcinoma, and it is
histologically and immunohistochemically
indistinguishable from its pulmonary or other
EPSmCC counterparts. Most patients present at
an advanced stage with widespread metastases
and a dismal prognosis despite multimodal
therapy. However, if the disease is found and
treated early, long-term survival may be possible for
patients with an organ-confined tumor [13].
2. Small cell carcinoma of the urinary bladder
SmCC of urinary bladder is a malignant neuroen-
docrine neoplasm derived from the urothelium which his-
tologically mimics its pulmonary counterpart. A recent
analysis from the Surveillance, Epidemiology, and End
Results of the SmCC of the urinary bladder database
indicated a significant rise in the incidence of the SmCC
of the urinary bladder in the United States from 0.05 to
0.14 cases per 100,000 people between 1991 and 2005
[15]. This is likely due to increase in the U.S. population’s
age. Similar to other bladder cancers, risk factors for
SmCC of urinary bladder include smoking, male sex
(male-female ratio of 3:1), and advanced age. The average
age of incidence was found to be 71.7 ± 11.2 years, with
a median age of 73 years [15]. Caucasians were most
commonly affected, with a white-nonwhite ratio of 10:1.
More than 60% of the SmCC of the lung has metastatic
disease at the time of diagnosis. Similar rates have been
shown in SmCC of the urinary bladder [11]. Chemother-
apy is the mainstay of treatment, with proven survival
benefit [16].
One study of immunohistochemical (IHC) stains in
SmCC of urinary bladder has shown that nuclear GATA3
expression was encountered in 7 bladder (7/22, 32%), 2
lung (2/15, 13%), and 0 (0/33, 0%) prostate SmCC [17].
TTF-1 expression in SmCC of urinary bladder was found
in 40% of the tumors in 2 studies, demonstrating that
TTF1 can be expressed in EPSmCC [18,19]. SmCC of
urinary bladder are also stained positive with the epithelial
markers: CAM 5.2, CK7, and EMA in 59%, 41%, and
77.7% of the cases, respectively. This supports the urothe-
lial origin of SmCC of urinary bladder [18,20]. Distingush-
ing SmCC of the prostate and from that of the bladder
can be very challenging, if even possible, because of low
positivity of GATA3 in SmCC of the bladder and low posi-
tivity of PSA and other prostatic markers, such as P501S,
in SmCC of the prostate [21,22].TERT promoter mutations, originally discovered in ~70%
of melanomas, have also been found to be the most
common form of genetic mutations in urothelial car-
cinomas. Interestingly, these mutations have very low
incidence in other prevalent carcinomas: lung, prostate
and colon cancers. Multiple studies [23-25], including
our unpublished results, demonstrated that up to 70-
80% of urothelial carcinoma carries the TERT promoter
mutations irrespective of grade, stage or location. Our
recent study [10] showed that 100% (10 cases) of SmCC
of the urinary bladder carry TERT promoter mutation
C228T, yet none of SmCC from all other origins includ-
ing prostate, lung, cervix, esophagus, and skin (Merkel
cell carcinoma) contain the TERT promoter mutations.
This study indicated that the TERT promoter mutation
may be a biomarker to distinguish SmCC of the urinary
bladder from SmCC of other origins.
3. Small cell carcinoma of the prostate
SmCC of the prostate was first described by Wenk et
al. [26] more than 30 years ago. Since then, it has been
reported to occur in 0.5–2% of men with prostate can-
cer, although autopsy studies of men who have died of
castration-resistant prostate cancer have reported the
presence of SmCC in up to 10–20% of cases [27,28].
Neuroendocrine markers such as chromogranin A and
synaptophysin are expressed in nearly all cases of con-
ventional prostatic adenocarcinoma, with the proportion
of cells that stain positive for these markers increasing
during castration [29]. In 24% and 35% of cases, p63 and
high-molecular-weight cytokeratin were noted to be
positive, which are typically negative in prostatic ade-
nocarcinoma [21]. Studies have demonstrated thyroid
transcription factor 1 (TTF-1) expression in over 50% of
SmCC of the prostate, limiting its utility in distinguishing
primary SmCC of the prostate from metastatic SmCC of
the lung [22]. PSA and other prostatic markers, such as
P501S, are only positive in about 17–25% cases, often
focally [21,22]. These results demonstrated that IHC stains
have very limited value to discriminate SmCC of prostate
from SCLC.
Interestingly, both conventional prostatic adenocarcin-
oma and SmCC of prostate share ERG gene rearrange-
ment which is absent in SmCC from other body sites.
This rearrangement occurs between an androgenregu-
lated gene, TMPRSS2 (21q22.3) and an ETS transcription
factor family member, most commonly ERG (21q22.2),
resulting in a gene fusion product, TMPRSS2–ERG gene
fusions. This result not only indicates a common clonal
origin between conventional prostatic adenocarcinoma
and SmCC of prostate, but also implies the clinical use
of ERG gene rearrangement as a biomarker to confirm a
prostatic origin for SmCC [30,31].
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The SmCC of gynecologic tract is one of the common
EPSmCCs, representing up to 2% of all gynecologic
malignancies [32,33]. Reported gynecologic sites include
the cervix, endometrium, ovary, fallopian tube, vagina
and vulva.
1. Small cell carcinoma of the uterine cervix (SmCCC)
The uterine cervix is the most common gynecologic
tract site involved with EPSmCCs. However, SmCCC is
a very rare disease, representing only 1% to 3% of all uterine
cervical cancers. SmCCC often coexists with conventional
squamous cell carcinoma or adenocarcinoma. Depending
on the series analyzed and the selection criteria employed,
between 11% and 64% of SmCCC cases present admixed
histology [34,35]. Immunohistochemical studies have
further revealed that the majority of cases show diffuse
nuclear and cytoplasmic p16 positivity [36,37].
The critical role of human papillomaviruses (HPV) in
the carcinogenesis of conventional cervical cancer is well
established. The prevalence of the different high-risk
HPV types in SmCCC has been preliminarily established
and reported to range from 50% to 100% [38,39]. It has
been found that unlike in squamous cell carcinoma of
the cervix, HPV 18 may be the most prevalent type of
SmCCC [37,40]. Given this evidence, SmCCC, like other
types of cervical cancer, seems to be associated with
high-risk HPV infection. For the purpose of differential
diagnosis, HPV is specific for SmCC of cervical origin
other than ovary or lung, but p16 immunohistochemis-
try is not useful for this purpose [36].
2. Small-cell carcinoma of the ovary
Small-cell ovarian carcinoma is divided into two cat-
egories: pulmonary type (SCCOPT) and hypercalcemic
type (SCCOHT). The cellular features and neuroendo-
crine markers of the pulmonary type resemble small-cell
carcinoma of the lung, whereas the immunohisto-
chemical markers and microscopic and ultrastructural
examination of SCCOHT do not [41]. Both of these
tumors are uncommon, but SCCOPT is extremely rare
with only approximately 20 cases reported in the English
literatures.
SCCOPT
The mean age of diagnosis of patients with SCCOPT is
51 years (22-85 years) [42]. Bilateral disease is present in
about half of the cases and all cases lack hypercalcemia
[42]. TTF-1 was found to be diffusely positive in one
case but absent in another case [36]. The diagnosis of
CSCOPT is exclusion of metastasis of SmCC from other
locations, in particular lung. One report showed thatmalignant transformation of ovarian mature cystic tera-
toma with a predominant pulmonary type small cell
carcinoma component, is CDX2 positive [43].
SCCOHT
SCCOHT represents less than 1% of all ovarian cancer
diagnoses, with fewer than 300 cases reported in the lit-
erature thus far [44,45]. The mean age of diagnosis is
23 years, and the majority of affected women present
with early-stage disease. Nonetheless, most patients relapse
and die within 2 years of diagnosis, regardless of tumor
stage, with a long-term survival rate of only 33%, even
when disease is confined to the ovary at diagnosis. The
tumor appears nearly almost unilaterally, mostly affect-
ing the right ovary [44,46].
Recently 3 independent studies reported that SCCOHT
is a monogenic disease caused by mutations in the
SMARCA4 gene. Whole-exome sequencing on DNA
obtained from 24 familial or sporadic cases of SCCOHT
revealed that 22 of the 24 cases analyzed were due to
SMARCA4 mutations; and Immunohistochemical analysis
of these cases and additional familial and non-familial
cases showed loss of SMARCA4 (BRG1) protein in 38 of
40 tumors [47]. Furthermore, the researchers suggest that
SCCOHT tumors are essentially malignant rhabdoid tu-
mors of the ovary, “they are not always comprised of small
cells, are not carcinomas, and only two thirds have hyper-
calcemia”. It is, therefore, possible that chemotherapeutic
regimens used to treat rhaboid tumors might help im-
prove the outcome of this disease. Ramos et al. [48]
reported that germline and somatic inactivating mutations
in the SWI/SNF chromatin-remodeling gene SMARCA4
in 75% (9/12) of SCCOHTcases in addition to SMARCA4
protein loss in 82% (14/17) of SCCOHT tumors but in
only 0.4% (2/485) of other primary ovarian tumors. Wit-
kowski et al also reported similar results. These new
pieces of evidence demonstrated that alterations in
SMARCA4, the major cause of SCCOHT, could lead to
improvements in genetic counseling and new treatment
approaches [46].
IV. Merkel cell carcinoma (MCC)
MCC is a rare neuroendocrine tumor of the skin with
rising incidence and an aggressive behavior. The annual
incidence of MCC is 0.6 per 100,000 persons and is in-
creasing (approximately 1,600 new cases per year in the
US) [49]. Histologically, MCC shares numerous features
with SmCC. Immunohistochemically, MCC stains posi-
tive for synaptophysin and chromogranin [50]. cytokera-
tin CK-20 is positive in 89–100% of Merkel cell tumors
with a punctate pattern and may be used to distinguish
MCC from other tumor types. However, 33% of small
cell lung cancers (SCLCs) and 3–4% of EPSmCCs also
stain positively for CK20 [51].
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omavirus, is clonally integrated in 70–80% of Merkel cell
carcinoma (MCC) tumors. MCV is part of the normal,
healthy skin flora but causes cancer after viral genome
mutations eliminate its replication capacity. While simi-
lar to known polyomaviruses, MCV oncogenes act in
new ways, such as activation of the survivin oncoprotein
and PP2A-independent targeting of cap-dependent trans-
lation [52,53]. Survivin inhibition improves survival of
mice bearing human MCC xenografts [54].
V. The origin of small cell carcinoma
The identification of the cell type(s) from which small
cell carcinoma originates is critical in the development
of methods for early diagnosis and treatment.
1. The cell of origin for small cell lung cancer
The usage of cell type-restricted Adeno-Cre vectors to
distinct cell populations in the lung of adult mouse
showed that loss of TP53 and RB1 can efficiently trans-
form neuroendocrine and Surfactant Protein C (SPC)-
expressing cells to SCLC, albeit SPC-expressing cells at
a lesser efficiency. In contrast, Clara cells were largely
resistant to transformation. These results indicate that
although neuroendocrine cells serve as the predominant
cell of origin for SCLC, a subset of SPC-expressing cells
may also be endowed with this ability [55,56].Table 1 Gene mutations in small cell carcinoma
Location Genes Small cell carcinoma
Lung TP53 mutation 80–90% [5]
RB1 mutation 60–90% [71]
PTEN mutation 60-90% of cases [8]
PARP1 high expression 2.6 fold higher than non-Sm
cell carcinoma [10]
Urinary bladder TERT promoter mutation 100%
TP53 overexpression 54% p53
negative staining 46% [72
Prostate ERG gene rearrangements 45% [30,31]
(TMPRSS2–ERG gene fusions)
RB1 loss 90% [68]
RAS/RAF No report
PTEN 63%[68]
SCCOHT SMARCA4 mutations 75-100% [46-48]
Merkel cell
carcinoma
MCV clonally integrated 80–97% [52-54]2. The cell of origin for EPSmCCs
The origin of EPSmCCs is controversial. It was assumed
that these neoplasms arise from neuroendocrine cells in
the Amine Precursor Uptake and Decarboxylation (APUD)
system [57,58]. To date, however, it is thought that the
origin of EPSmCCs is either a totipotent stem cell capable
of differentiating into a variety of cell types, or that ele-
ments of SmCC arise as a late-stage phenomenon in the
genetic progression of carcinomas [57]. The presence of
mixed carcinomas may have implications for the origin of
EPSmCC, which may arise from multipotent stem cells
that retain the ability to differentiate into various tissue
types. Evidence for this hypothesis comes from an identi-
cal pattern of allelic loss in SmCC of urinary bladder
mixed with urothelial carcinoma (UC) [59]. For bladder
localizations, a malignant transformation of the neuroen-
docrine cells physiologically located in the urothelium has
been proposed [60]. Molecular genetic studies have also
suggested a common clonal origin for the coexisting
bladder SmCC and conventional UC [59,61]. X chromo-
somal inactivation analysis [59] in females illustrated
the same nonrandom inactivation in both SmCC of the
urinary bladder and UC. Identical point mutations of
TP53 were found in invasive bladder SmCC and coex-
isting UC in situ; additionally, no loss of heterozygos-
ity of 9 microsatellite markers and TP53 was found in




all PARP-1 inhibitors as anti-cancers
60-70% Not see in SmCC from prostate, lung,
ovary, or esophagus [10]
]
TP53 mutations 14% 30%
40-60% [63] True prostate cancer specific
biomarkers: PCA3 and TMPRSS2:ERG
gene fusion [73]
34% of primary 74%
of met [14]
Loss of RB1 function late in
prostate cancer, early in other
common cancers
43% of primary, 90%
of met [14]
4% of primary, 58%
of met [14]
Very rare in other
tumor [46-48]
Characteristic mutation in SCCOHT
8-16% of other
tumor [52-54]
Characteristic integration in MCC
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situ [61].
Other theories of histogenesis include metaplasia from
other high-grade malignancies. Neuroendocrine (NE)
cells are detected by IHC in some in-situ cervical adeno-
carcinomas, and these may be the origin of cervical NE
carcinomas [62]. Further support for this theory comes
from a study where identical loci with loss of heterozy-
gosity were demonstrated in mixed adenocarcinoma and
EPSmCC of the appendix, and an additional locus was
found in the EPSmCC component [63]. Similarly, add-
itional loci with loss of heterozygosity were noted in
breast EPSmCC compared with adjacent ductal carcin-
oma in situ.
There is a high concordance rate of ERG rearrange-
ment between the SmCC of prostate and prostatic acinar
components in a given patient; however, the absence of
ERG rearrangement in bladder or lung small cell carcin-
omas supports a common origin for these two subtypes
of prostate cancer.
In one report, malignant transformation of ovarian
mature cystic teratoma consists of a predominant pul-
monary type SmCC component (65%), as well as minor
components including adenocarcinoma (25%), squamous
cell carcinoma (5%), and transitional cell carcinoma (5%).
CDX2 positivity was retained in all of the carcinomas. It
may suggest that the adenocarcinoma had arisen from an
intestinal epithelium in the mature cystic teratoma and
then differentiated into the diverse histological types men-
tioned above [43].
Recent reports [46,48] also revealed that small cell car-
cinoma of the ovary, hypercalcemic type, display frequent
inactivating germline and somatic mutations in SMARCA4,
a mutation rare in other common tumors. It has been well
established that Merkel cell virus is strongly associated
with only Merkel cell carcinoma, but not SmCC of any
other origins [52].
Loss of RB1 function is associated with the development
of neuroendocrine tumors, including prostate, pituitary,
thyroid and adrenal gland tumors [64-67]. This mutation
may give this type of cancer mutual morphologic features.
Loss of RB1 by deletion is a common event in prostatic
small cell carcinoma (90, 26/29), but rarely occurs in high-
grade acinar tumors (7%, 10/150) and primary acinar car-
cinomas with neuroendocrine differentiation (11%, 4/35)
[68]. General inactivation of the RB1 pathway and deregu-
lation of the cell cycle was a common early event in hu-
man cancers [69,70], however homozygous deletion of
RB1 is a relatively late-stage genomic alteration in acinar
prostate cancer progression [68].
These results suggested that at least some EPSmCC
has the same cell origin of conventional carcinoma,
such as urothelial carcinoma, prostatic adenocarcin-
oma, et al.Conclusion
Current evidences strongly suggest that despite signifi-
cant overlap of morphology and immunophenotype
among SmCCs from different anatomic sites, SmCCs
have heterogeneous molecular mutations (Table 1). A
genetically oriented approach for the diagnosis and ther-
apy of SmCCs becomes necessary for significant clinical
impact on the prognosis and therapy outcome of this
heterogeneous group of aggressive malignancies.
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